Health and Healthcare

Stem Cell Stocks Take Off (ASTM, GERN, OPXA, STEM)

Tickerspy’s Stem Cell Stock Index (*RSXTM) took off today, rising nearly 13%.  The movement followed a release from the National Institutes of Health  (NIH) announcing that 13 embryonic stem cell lines were approved for funding.

Opexa Therapeutics Inc (NASDAQ: OPXA) led the rise in stem cell stocks, surging over 40%.  The company seeks to develop treatments to major illnesses, such as multiple sclerosis and diabetes, through stem cell research.  The company’s stock has risen 2837% off its lows for the year.

StemCells Inc (NASDAQ: STEM) rose over 30% to a high of $1.45.  The company engages in research aimed at developing treatment for organ damage using stem cells.  The company’s stock is up over 1544% off its low for the year.

Garrett W. McIntyre

Find a Qualified Financial Advisor (Sponsor)

Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.